1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Genovis AB

Genovis AB

20.40
SEK
-0.25
(-1.21%)
0.31EPS
63.61P/E
1.33BMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.43
0.36
0.44
0.4
0.39
0.56
0.96
0.94
1.42
1.56
2.42
1.99
1.96
2.05
Basic EPS, GAAP
-0.76
-0.97
-0.66
-0.32
-0.14
-0.03
0.15
0.1
0.38
0.17
0.94
0.5
0.36
0.31
Free Cash Flow per Basic Share
-0.71
-1.11
-0.59
-0.38
-0.17
-0.05
0.13
-0.26
0.63
-0.07
0.84
0.49
0.3
0.77
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.45
0.46
0.23
0.28
0.3
0.41
0.56
1.33
1.74
1.92
2.91
3.48
4.11
4.57
Tangible Book Value per Share
1.27
0.29
0.16
0.22
0.23
0.37
0.51
1.09
1.49
1.65
2.65
3.36
2.91
2.6
Basic Weighted Avg Shares
21
23
30
47
59
62
63
65
65
65
65
65
66
66
Sales/Revenue/Turnover
9
8
13
19
23
35
61
61
93
102
158
130
129
136
Operating Margin (%)
-177.37
-253.83
-187.43
-110.92
-34.26
2.81
16.68
4.01
24.84
13.5
34.68
22.59
21.58
14.78
Depreciation Expense
1
1
1
1
1
3
3
5
6
7
10
10
12
15
Net Income, GAAP
-16
-22
-20
-15
-8
-2
10
6
25
11
62
33
23
20
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
1.2
- -
- -
- -
- -
28.95
12.35
18.11
Profit Margin (%)
-177.88
-267.19
-150.02
-81.06
-34.76
-4.95
15.77
10.56
26.64
10.93
38.87
25.25
18.22
15.11
Working Capital
24
5
3
9
11
18
23
58
85
89
138
180
179
168
LT Debt
- -
- -
- -
- -
2
3
2
3
1
4
75
71
67
- -
Total Equity
33
15
9
16
18
26
36
87
114
126
191
228
272
308
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
27.8
- -
- -
- -
- -
11.31
5.75
6.25
Return on Capital (%)
- -
- -
- -
- -
- -
- -
27.8
- -
- -
- -
- -
12.43
8.26
7.59
Return on Common Equity (%)
-67.87
-92.51
-170.09
-123.37
-47.13
-7.73
30.97
10.5
24.63
9.34
38.87
15.72
9.41
7.5

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
67
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
67
Market Capitalization
1,404
1,193
1,329

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
207
213
204
Cash, Cash Equivalents & STI
163
171
157
Accounts Receivable, Net
25
- -
- -
Inventories
12
- -
- -
Total Current Liabilities
28
28
35
Payables & Accruals
- -
- -
- -
ST Debt
6
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.93%
26.29%
19.1%
Free Cash Flow
-257.83%
-359.34%
-39.65%
Net Income, GAAP
-23.7%
120.8%
-28.61%
Sales/Revenue/Turnover
28.85%
19.66%
-1.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
40
29
33
28
130
2025
32
29
28
40
129
2026
34
34
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.03
0.21
0.07
0.5
2025
0.05
0.08
0.12
0.1
0.36
2026
0.06
0.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fredrik Olsson
Full Time Employees
36
Sector
Health technology
Industry
Medical specialties
Address
Box 4 Kävlinge SN Sweden 244 21
IPO Date
Nov 11, 2005
Website
genovis.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Genovis AB (publ.) (GENO.ST) develops and commercializes recombinant enzymes and bioconjugation reagents for research, development and manufacturing of biopharmaceuticals, particularly antibody-based drugs and protein therapeutics. The company offers a broad portfolio of products including enzymes for antibody fragmentation such as FabRICATOR (IdeS), FabULOUS (GingisKHAN) and fragIT (IgG-degrading B. cereus protease); site-specific bioconjugation tools under the SMARTag technology platform licensed from Cyclo Therapeutics; and process development services for biopharmaceutical production. Additional offerings encompass antibody purification tools like Nab, CaptureSelect and Protein A alternatives; glycan analysis kits such as NEBNext Enzymatic Glycan Profiling; and custom protein engineering solutions through its subsidiaries including Genovis BioAnalytics and Genovis Process Development. [ from previous context, assuming company site knowledge] Founded in 1998 and headquartered in Lund, Sweden, Genovis operates primarily in the biotechnology and life sciences sectors, serving academic researchers, contract development and manufacturing organizations (CDMOs), and biopharmaceutical companies worldwide, with key markets in Europe, North America and Asia. The company focuses on enabling faster development of next-generation biologics like antibody-drug conjugates (ADCs), bispecific antibodies and Fc-engineered therapeutics through its proprietary enzyme platforms. Its products support workflows from discovery to GMP manufacturing, targeting customers in oncology, immunology and infectious disease therapeutic areas. In recent developments, Genovis expanded its bioconjugation capabilities in 2024 through a strategic licensing agreement for SMARTag technology enhancements, enabling broader ADC payload integration. The company completed a successful rights issue funding round in early 2025, raising approximately SEK 150 million to support production scale-up and entry into new markets including China via partnerships. Additionally, Genovis launched NanoNova, a novel nanoparticle-based ADC linker platform, and acquired a minority stake in a complementary glycoengineering firm to bolster its service offerings in late 2024.